Mark Kester
Impact in
- Molecular Biology top 0.5%
- Sphingolipid Metabolism and Signaling
- Lipid Membrane Structure and Behavior
- Ophthalmology top 0.5%
Papers in
-
- Sphingolipid Metabolism and Signaling 82
- Lipid Membrane Structure and Behavior 36
- Protein Kinase Regulation and GTPase Signaling 21
- Cell Biology 31
- Co-authors
- Todd E. FoxJames H. AdairLakshman SandirasegaraneJong K. YunNicole A. BourbonHong‐Gang WangErhan İ. AltınoğluBrian M. Barth
- Journals
- Journal of Biological Chemistry (12 papers)The FASEB Journal (7 papers)Cancer Biology & Therapy (7 papers)ACS Nano (6 papers)Journal of Lipid Research (6 papers)
- Partner nations
- United StatesEgyptSpain
In The Last Decade
Mark Kester
217 papers receiving 11.0k citations
Hit Papers
Peers
Comparison fields: 5 of 148
- Molecular Biology 6.4k
- Ophthalmology 700
- Cell Biology 1.2k
- Biomaterials 830
- Physiology 286
Countries citing papers authored by Mark Kester
This map shows the geographic impact of Mark Kester's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Kester with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Kester more than expected).
Fields of papers citing papers by Mark Kester
This network shows the impact of papers produced by Mark Kester. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Kester. The network helps show where Mark Kester may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Kester, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 5 | |
| 2 | 2022 | 13 | |
| 3 | 2021 | 51 | |
| 4 | 2021 | 4 | |
| 5 | 2020 | 6 | |
| 6 | 2020 | 14 | |
| 7 | 2019 | 23 | |
| 8 | 2019 | 37 | |
| 9 | 2019 | 35 | |
| 10 | 2017 | 45 | |
| 11 | 2016 | 13 | |
| 12 | 2012 | 300 | |
| 13 | Elsevier's integrated review pharmacology | 2012 | 17 |
| 14 | 2012 | 26 | |
| 15 | 2009 | 22 | |
| 16 | 2008 | 16 | |
| 17 | 2007 | 155 | |
| 18 | Elsevier's integrated pharmacology | 2007 | 2 |
| 19 | A combinatorial approach using sorafenib and liposomal ceramide to inhibit malignant melanoma | 2007 | 1 |
| 20 | Bar coding at the bedside. New England hospital implements an automated point-of-care medication administration system to reduce medication errors and their associated complications. | 2004 | 3 |
About Mark Kester
Mark Kester is a scholar working on Molecular Biology, Cell Biology, Physiology, Physiology and Biochemistry, having authored 222 papers that have together received 11.2k indexed citations. Recurring topics across this work include Sphingolipid Metabolism and Signaling (82 papers), Lipid Membrane Structure and Behavior (36 papers), Total Knee Arthroplasty Outcomes (31 papers), Orthopaedic implants and arthroplasty (30 papers), Protein Kinase Regulation and GTPase Signaling (21 papers), Orthopedic Infections and Treatments (17 papers), Drug Transport and Resistance Mechanisms (16 papers) and Nitric Oxide and Endothelin Effects (15 papers). The work is most often cited by research in Molecular Biology (6.4k citations), Ophthalmology (700 citations), Cell Biology (1.2k citations), Biomaterials (830 citations) and Physiology (286 citations). Mark Kester has collaborated with scholars based in United States, Egypt and Spain. Frequent co-authors include Todd E. Fox, James H. Adair, Lakshman Sandirasegarane, Jong K. Yun, Nicole A. Bourbon, Hong‐Gang Wang, Erhan İ. Altınoğlu, Brian M. Barth, Gavin P. Robertson and Megan M. Young. Their work appears in journals such as Journal of Biological Chemistry, The FASEB Journal, Cancer Biology & Therapy, ACS Nano and Journal of Lipid Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.